Resverlogix Corp T.RVX

Discussions Involve Multiple Partners in Varying Formats

[Jesus4Prez]

DM said "We have multiple partners we are discussing in multiple different formats."  Could this be a hint toward a full buyout, not just a 'partnership'?

"The development of this company is 'straight up from here'."  Could this be insinuation that the share price will spike?

J4P

[QualityTest]

Buyout is the more optimistic implication from that statement. GV and I discussed other options being global licensing deals like they have with Medison (Israel) or discussions between multiple SGLT2 companies. Given where the share price is now, it will spike even on a partnership announcement.

[general360]

Are all SGLT's created equal? I wonder if there's any different synergies amongst the different SGLT's. Similar to what we saw with differences between statins with the RCT, Crestor better than Lipitor? I don't know that we've seen any data to answer.  When DM made the comment in the Prezzy, "we didn't get the bump we should've", around feb, we were

[QualityTest]

I don't recall seeing any data tha differentiated SGLTs either so afaik none have been shown to work significantly better than others.  I've seen you mention $8/share before from Agoracom. I think that was just one poster's guess as to where we would be at in August. Nothing scientific or from a company source. I think upfront payment will be >$100m as well, but trying not to

[general360]

hte origins of the $8 was from agora. it was a poster who seemed to indicate that it was the whisper estimates for where we should be.  i'm thinking it's true, that it was the whisper #, basically cause it lines up w/ DM's direct stmt of 4-5x bump.  that's 4-5x PRE covid, so about 1.30/1.40/1.45 * 4-5 is about 7$.  seems to line up w/ that whisper...  we also

[QualityTest]

General, Your comment about SGLT2s got me wondering about DPP4s. From RVX's Jan 13 NR:  "When apabetalone was applied to top standard of care in diabetes patients their risk of MACE events was greatly reduced. In total, approximately 25% of BETonMACE patients were on new oral anti-diabetic treatments that included SGLT2 and DPP4 inhibitors. In combination with apabetalone, primary

[G1945V]

QT, yes, I agree with your last comment.  https://www.resverlogix.com/investors/news?article=655   "Jardiance (co-owned by Boehringer Ingelheim and Eli Lilly) and Januvia (Merck & Co.) are the current SGLT2i and DPP4i market leaders, respectively. The market penetration of these treatments is expected to grow significantly over the next five years, with the potential

[general360]

dont forget about the DPP4 inhibitors and apparently GLP-1 receptor agonists. Over at agora Bear speculates "Resverlogix has probably filed similar patents for apabetalone in combo with DPP4 inhibitors and GLP-1 receptor agonists, with which Resverlogix has also dropped hints that there was synergy with apabetalone." same questions for SGLT's/DPP4s/GLP as for statins: Are all SGLT&

[narmac]

,,,,yessss,,,,, I am waiting for that deep pocket entity to start taking shares at the ask right up to the $3 level,,,,,,,,,,,,,,,,,,,,its coming,,,,,,,,,,,if there is big money to be made here RVX will not be left to sit and mould before our anticipated news,,,,,,,,,,,,,,,,I find it very hard to believe we are going to be in wait mode for that very news and then to spike up,,,,,,,, investors who